<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.116415</article-id><article-id pub-id-type="publisher-id">ACM-43469</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210600000_68948633.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  lncRNA PCAT14对甲状腺癌细胞侵袭转移的影响
  Effects of lncRNA PCAT14 on Invasion and Metastasis of Thyroid Cancer Cells
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>烨梅</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>华</surname><given-names>慧</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>晓琴</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>山东第一医科大学(山东省医学科学院)，山东省肿瘤防治研究院(山东省肿瘤医院)中心实验室，山东 济南</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>06</month><year>2021</year></pub-date><volume>11</volume><issue>06</issue><fpage>2857</fpage><lpage>2865</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨lncRNA PCAT14对甲状腺癌细胞增殖和侵袭的影响及其分子机制。方法：生物信息学方法预测lncRNA PCAT14表达与肾癌患者临床分期的相关性。选择TPC-1甲状腺癌细胞系转染，分别将PCAT14质粒(实验组)或空载对照质粒(对照组)转至甲状腺癌细胞中。使用qPCR检测PCAT14质粒转染效率。细胞计数实验及克隆形成实验检测转染后细胞增殖活性，Transwell侵袭实验检测转染后甲状腺细胞的侵袭能力。Western blot检测EMT相关标记物的蛋白表达水平。生物信息学方法预测lncRNA PCAT14可能结合的蛋白。结果：TCGA数据库显示，甲状腺癌组织lncRNA PCAT14相对表达水平显著低于癌旁正常组织(P &lt; 0.05)。lncRNA PCAT14在甲状腺癌晚期患者肿瘤组织中相对表达量更低(P &lt; 0.01)。与对照组比较，实验组lncRNA PCAT14相对表达水平显著升高(P &lt; 0.05)，细胞增殖活性(P &lt; 0.05)和细胞的侵袭能力显著降低(P &lt; 0.01)。同时，实验组lncRNA PCAT14过表达抑制了EMT相关蛋白的表达。lncRNA PCAT14可能与DBX2结合发挥生物学功能。结论：lncRNA PCAT14在甲状腺癌组织中低表达，与肾癌患者临床分期相关。过表达lncRNA PCAT14可明显抑制肾癌细胞增殖和侵袭，其分子机制可能为lncRNA PCAT14与DBX2结合发挥生物学功能。
   Objective: To investigate the effect of lncRNA PCAT14 on the invasion and metastasis of thyroid cancer cells and its molecular mechanism. Methods: Bioinformatics methods predict the correlation between the expression of lncRNA PCAT14 and the clinical stage of renal cancer patients. Select TPC-1 thyroid cancer cell line for transfection, and transfer PCAT14 plasmid (experimental group) or empty control plasmid (control group) to thyroid cancer cells respectively. QPCR was used to detect the transfection efficiency of PCAT14 plasmid. Cell counting experiment and clone formation experiment were used to detect cell proliferation activity after transfection, and Transwell invasion experiment was used to detect the invasion ability of thyroid cells after transfection. Western blot was used to detect the protein expression level of EMT-related markers. Bioinformatics methods predict the protein that lncRNA PCAT14 may bind. Results: The TCGA database showed that the relative expression level of lncRNA PCAT14 in thyroid cancer tissues was significantly lower than that in normal tissues adjacent to cancer (P &lt; 0.05). The relative expression of lncRNA PCAT14 is lower in the cancer tissues of patients with advanced thyroid cancer (P &lt; 0.01). Compared with the control group, the relative expression level of lncRNA PCAT14 of the experimental group was significantly increased (P &lt; 0.05), and the cell proliferation activity (P &lt; 0.05) and cell invasion ability were significantly reduced (P &lt; 0.01). At the same time, the lncRNA PCAT14 overexpression in the experimental group inhibited the expression of EMT-related proteins. lncRNA PCAT14 may combine with DBX2 to exert biological functions. Conclusion: lncRNA PCAT14 is lowly expressed in thyroid cancer tissues and is related to the clinical stage of renal cancer patients. Overexpression of lncRNA PCAT14 can significantly inhibit the proliferation and invasion of renal cancer cells. The molecular mechanism may be that lncRNA PCAT14 combine with DBX2 to exert biological functions.
 
</p></abstract><kwd-group><kwd>甲状腺癌，lncRNA PCAT14，侵袭，转移, Thyroid Cancer</kwd><kwd> lncRNA PCAT14</kwd><kwd> Invasion</kwd><kwd> Metastasis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨lncRNA PCAT14对甲状腺癌细胞增殖和侵袭的影响及其分子机制。方法：生物信息学方法预测lncRNA PCAT14表达与肾癌患者临床分期的相关性。选择TPC-1甲状腺癌细胞系转染，分别将PCAT14质粒(实验组)或空载对照质粒(对照组)转至甲状腺癌细胞中。使用qPCR检测PCAT14质粒转染效率。细胞计数实验及克隆形成实验检测转染后细胞增殖活性，Transwell侵袭实验检测转染后甲状腺细胞的侵袭能力。Western blot检测EMT相关标记物的蛋白表达水平。生物信息学方法预测lncRNA PCAT14可能结合的蛋白。结果：TCGA数据库显示，甲状腺癌组织lncRNA PCAT14相对表达水平显著低于癌旁正常组织(P &lt; 0.05)。lncRNA PCAT14在甲状腺癌晚期患者肿瘤组织中相对表达量更低(P &lt; 0.01)。与对照组比较，实验组lncRNA PCAT14相对表达水平显著升高(P &lt; 0.05)，细胞增殖活性(P &lt; 0.05)和细胞的侵袭能力显著降低(P &lt; 0.01)。同时，实验组lncRNA PCAT14过表达抑制了EMT相关蛋白的表达。lncRNA PCAT14可能与DBX2结合发挥生物学功能。结论：lncRNA PCAT14在甲状腺癌组织中低表达，与肾癌患者临床分期相关。过表达lncRNA PCAT14可明显抑制肾癌细胞增殖和侵袭，其分子机制可能为lncRNA PCAT14与DBX2结合发挥生物学功能。</p></sec><sec id="s2"><title>关键词</title><p>甲状腺癌，lncRNA PCAT14，侵袭，转移</p></sec><sec id="s3"><title>Effects of lncRNA PCAT14 on Invasion and Metastasis of Thyroid Cancer Cells<sup> </sup></title><p>Yemei Song, Hui Hua, Xiaoqin Li</p><p>Shandong Provincial Key Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan Shandong</p><p><img src="//html.hanspub.org/file/57-1572330x4_hanspub.png" /></p><p>Received: May 24<sup>th</sup>, 2021; accepted: Jun. 13<sup>th</sup>, 2021; published: Jun. 28<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/57-1572330x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the effect of lncRNA PCAT14 on the invasion and metastasis of thyroid cancer cells and its molecular mechanism. Methods: Bioinformatics methods predict the correlation between the expression of lncRNA PCAT14 and the clinical stage of renal cancer patients. Select TPC-1 thyroid cancer cell line for transfection, and transfer PCAT14 plasmid (experimental group) or empty control plasmid (control group) to thyroid cancer cells respectively. QPCR was used to detect the transfection efficiency of PCAT14 plasmid. Cell counting experiment and clone formation experiment were used to detect cell proliferation activity after transfection, and Transwell invasion experiment was used to detect the invasion ability of thyroid cells after transfection. Western blot was used to detect the protein expression level of EMT-related markers. Bioinformatics methods predict the protein that lncRNA PCAT14 may bind. Results: The TCGA database showed that the relative expression level of lncRNA PCAT14 in thyroid cancer tissues was significantly lower than that in normal tissues adjacent to cancer (P &lt; 0.05). The relative expression of lncRNA PCAT14 is lower in the cancer tissues of patients with advanced thyroid cancer (P &lt; 0.01). Compared with the control group, the relative expression level of lncRNA PCAT14 of the experimental group was significantly increased (P &lt; 0.05), and the cell proliferation activity (P &lt; 0.05) and cell invasion ability were significantly reduced (P &lt; 0.01). At the same time, the lncRNA PCAT14 overexpression in the experimental group inhibited the expression of EMT-related proteins. lncRNA PCAT14 may combine with DBX2 to exert biological functions. Conclusion: lncRNA PCAT14 is lowly expressed in thyroid cancer tissues and is related to the clinical stage of renal cancer patients. Overexpression of lncRNA PCAT14 can significantly inhibit the proliferation and invasion of renal cancer cells. The molecular mechanism may be that lncRNA PCAT14 combine with DBX2 to exert biological functions.</p><p>Keywords:Thyroid Cancer, lncRNA PCAT14, Invasion, Metastasis</p><disp-formula id="hanspub.43469-formula69"><graphic xlink:href="//html.hanspub.org/file/57-1572330x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/57-1572330x7_hanspub.png" /> <img src="//html.hanspub.org/file/57-1572330x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>甲状腺癌(Thyroid Cancer, THCA)是世界上最常见的内分泌恶性肿瘤，发病率占所有癌症类型的1%~2% [<xref ref-type="bibr" rid="hanspub.43469-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.43469-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.43469-ref3">3</xref>]。其中乳头状癌是最常见的病理类型，占甲状腺肿瘤所有病理类型80%~85% [<xref ref-type="bibr" rid="hanspub.43469-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.43469-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.43469-ref6">6</xref>]。目前，大部分甲状腺癌患者通过手术切除和化疗或放疗后预后良好 [<xref ref-type="bibr" rid="hanspub.43469-ref7">7</xref>]。然而，少数乳头状甲状腺癌患者由于原发肿瘤较大、淋巴结转移、远处转移等临床病理特点，预后较差 [<xref ref-type="bibr" rid="hanspub.43469-ref8">8</xref>]。因此对甲状腺癌发生发展分子机制研究对其诊断和预后判断具有非常重要的临床价值。</p><p>长链非编码RNA是一种长度在200~100,000核苷酸之间的单链非编码RNA分子 [<xref ref-type="bibr" rid="hanspub.43469-ref9">9</xref>]。长链非编码RNA在细胞功能中发挥重要作用，其调控可使遗传输出多样化，其对基因网络的微调是必不可少的，其失调与癌症的发病机制密切相关 [<xref ref-type="bibr" rid="hanspub.43469-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.43469-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.43469-ref12">12</xref>]。已有研究表明lncRNA PCAT14在前列腺癌和肝癌中发挥促进肿瘤发展的作用 [<xref ref-type="bibr" rid="hanspub.43469-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.43469-ref14">14</xref>]，但尚未见其在甲状腺癌中的报道。本研究旨在探讨lncRNA PCAT14在甲状腺乳头状癌中的表达及其对肿瘤生物学行为的影响，为甲状腺乳头状癌的诊断、预后评估和靶向治疗提供参考。</p><sec id="s5_1"><title>1.1. 资料和方法</title><sec id="s5_1_1"><title>1.1.1. 一般资料</title><p>甲状腺癌组织样本的大规模lncRNA表达谱数据来源于TCGA，基于RNA测序结果获得512个甲状腺癌组织样本和337个正常对照组织样本的转录组数据。</p></sec><sec id="s5_1_2"><title>1.1.2. 试剂及细胞</title><p>甲状腺癌细胞(BCPAP, TPC-1)购自中国科学院典型培养物保藏委员会细胞库；1640培养基和DMEM高糖培养基购自美国Corning公司；胎牛血清和胰酶购自Gibco公司；PCAT14质粒和阴性对照质粒购自金唯智；Transwell小室购自美国Corning公司；引物购自上海吉玛公司；jetPRIME转染试剂购自法国Polyplus公司；逆转录试剂盒购自TAKARA公司；结晶紫购自中国国药集团公司；甲醇购自国药集团化学试剂有限公司。TRIzol购自美国Invitorgen公司；RIPA裂解液、5&#215;蛋白上样缓冲液购自北京索莱宝公司；Tris、SDS、甘氨酸购自上海生工生物工程有限公司；抗体购自武汉三鹰生物技术有限公司。</p></sec></sec><sec id="s5_2"><title>1.2. 方法</title><sec id="s5_2_1"><title>1.2.1. 生物信息学方法</title><p>采用TCGA数据库对甲状腺癌和癌旁正常组织中lncRNA PCAT14的差异表达进行分析。采用RNA-蛋白互作预测网站(RNA-Protein Interaction Prediction (RPISeq) (iastate.edu))预测与lncRNA PCAT14结合的蛋白。</p></sec><sec id="s5_2_2"><title>1.2.2. 细胞培养和细胞转染</title><p>用含10%FBS的1640培养基培养BCPAP和TPC-1甲状腺癌细胞，培养条件为恒温37℃，饱和湿度，5% CO<sub>2</sub>浓度。细胞每隔1~2天进行换液或传代。取对数生长期细胞接种于无菌12孔板内，待细胞融合达40%~50%左右时使用jetPRIME转染试剂进行质粒转染。实验组为PCAT14质粒，阴性对照组为空载质粒，转染6小时后换液。</p></sec><sec id="s5_2_3"><title>1.2.3. 提取RNA及实时荧光定量PCR</title><p>使用Trizol法提取细胞总RNA，将RNA逆转录成cDNA。以β-actin引物为内参，使用lncRNA PCAT14引物进行qPCR扩增，检测PCAT14在细胞中表达量。实验步骤严格参照实时定量PCR试剂说明书操作。实验数据采用2-ΔΔCt法计算。lncRNA PCAT14引物F：5’-CAAGAATGGGCCATAGTGACG-3’，R：5’-GCACAGCCCTAGATCCCTTA-3’。β-actinF：5’-GGCGGCACCACCATGTACCCT-3’，R：5’-AGGGGCC GGACTCGTCATACT-3’。</p></sec><sec id="s5_2_4"><title>1.2.4. 细胞计数实验</title><p>取进行转染处理的细胞，分别在转染24 h后第0、24、48、72 h计数。用10 μL枪头吸取已消化悬浮的细胞，从计数板边缘缓缓滴入，使之充满计数板和盖玻片之间的空隙中。显微镜下计算计数板四大格细胞总数，压线细胞只计左侧和上方的。计算公式：细胞数/mL = (4大格细胞总数/4) &#215; 10,000，重复6次，取平均值。</p></sec><sec id="s5_2_5"><title>1.2.5. 克隆形成实验</title><p>取转染处理24 h后的细胞按照每孔1000个细胞均匀铺于6孔板中，37℃恒温培养箱中孵育8~10天后取出，0.5%结晶紫甲醇溶液固定染色后计算克隆形成率。</p></sec><sec id="s5_2_6"><title>1.2.6. Transwell侵袭实验</title><p>下室中加入600 μL无菌PBS放置于培养箱中激活小室，30 min后弃之。Transwell下室中加入600 ul含1% FBS的1640培养基，取实验组及对照组转染24 h后的细胞，用无血清培养基重悬后接种到上室，每个小室4 &#215; 10<sup>4</sup>个细胞。36 h后取出小室，用0.5%结晶紫甲醇溶液固定染色20 min，用清水冲洗小室上层，湿棉棒小心擦去上室膜表面上的细胞，自然晾干。在显微镜下随机选取5~7个视野拍照，image J统计实验结果。</p></sec><sec id="s5_2_7"><title>1.2.7. Western Blot</title><p>取转染后48 h细胞提取总蛋白。定量后各取5 ug蛋白上样电泳及转膜，室温封闭2 h后剪膜，分别与一抗4℃孵育过夜，三次洗膜后分别与二抗室温孵育1 h，洗膜后用显影液孵育2 min，采用凝胶成像分析仪曝光显影。</p></sec></sec><sec id="s5_3"><title>1.3. 统计学分析</title><p>所有数据均采用SPSS19.0软件进行分析。符合正态分布的数据资料使用 x &#175; &#177; s 表示，两独立样本比较采用独立样本t检验，组间比较使用单因素方差分析。所有实验均重复3次，以P &lt; 0.05认为差异有统计学意义。</p></sec></sec><sec id="s6"><title>2. 结果</title><sec id="s6_1"><title>2.1. 甲状腺癌中lncRNA PCAT14表达与肿瘤临床分期相关</title><p>分析TCGA数据库中512个甲状腺癌组织样本与337个癌旁组织样本lncRNA PCAT14的表达量，结果显示lncRNA PCAT14在甲状腺癌组织中表达量低于癌旁正常组织。差异有统计学意义(P &lt; 0.05，图1)。同时，基于TCGA数据库分析显示lncRNA PCAT14与肿瘤临床分期相关，在Ⅲ期和Ⅳ期甲状腺癌组织中lncRNA PCAT14表达量更低(P &lt; 0.01，图2)。</p><p>图1. TCGA数据库中lncRNA PCAT14在甲状腺癌和癌旁组织中的表达</p><p>图2. TCGA数据库中不同临床分期肿瘤组织中lncRNA PCAT14的表达量</p></sec><sec id="s6_2"><title>2.2. 过表达lncRNA PCAT14对甲状腺癌BCPAP细胞增殖能力的影响</title><p>细胞计数结果显示，转染PCAT14质粒实验组的细胞增殖能力第三天时明显低于空载转染组，分别为26.125 &#177; 0.215、43 &#177; 0.364，差异有统计学意义(P &lt; 0.05，图3)。克隆形成实验结果显示，转染PCAT14质粒实验组的细胞克隆形成率低于空载转染组，分别为0.44 &#177; 0.030、1.03 &#177; 0.021，差异有统计学意义(P &lt; 0.01，图4)。提示过表达lncRNA PCAT14后可以抑制TPC-1细胞增殖能力。</p><p>图3. 细胞计数检测lncRNA PCAT14对TPC-1细胞增殖能力的影响</p><p>图4. 克隆形成实验检测lncRNA PCAT14对TPC-1细胞增殖能力的影响</p></sec><sec id="s6_3"><title>2.3. 过表达lncRNA PCAT14对甲状腺癌BCPAP细胞侵袭能力的影响</title><p>Transwell侵袭实验结果显示，PCAT14转染组每个高倍视野下穿膜细胞数低于空载转染组，分别为0.315 &#177; 0.012、1.015 &#177; 0.031，差异有统计学意义(P &lt; 0.01，图5)。提示过表达lncRNA PCAT14后可以抑制TPC-1细胞侵袭能力。</p><p>图5. Transwell侵袭实验检测lncRNA PCAT14对TPC-1细胞侵袭能力的影响</p></sec><sec id="s6_4"><title>2.4. 过表达lncRNA PCAT14对TPC-1细胞中上皮–间质转化 (Epithelial-Mesenchymal Transition, EMT)相关蛋白表达的影响</title><p>Western blot实验结果表明，与空载转染组相比，PCAT14转染组N-cadherin、vimentin和TAZ的蛋白表达水平下降(图6)。提示过表达lncRNA PCAT14抑制了TPC-1细胞发生上皮－间质转化。</p></sec><sec id="s6_5"><title>2.5. lncRNA PCAT14结合蛋白的预测</title><p>RNA-蛋白互作预测网站(RNA-Protein Interaction Prediction (RPISeq) (iastate.edu))显示与lncRNA PCAT14互作的蛋白为DBX2，结合评分中RF = 0.7，SVM- = 0.92。</p><p>图6. Western blot检测TPC-1细胞N-cadherin、Vimentin和TAZ蛋白表达</p></sec></sec><sec id="s7"><title>3. 讨论</title><p>在过去的几十年里，甲状腺乳头状癌的发病率一直在快速上升。虽然甲状腺乳头状癌患者预后一般较好，但肿瘤的侵袭性和转移性是导致预后不良的主要危险因素 [<xref ref-type="bibr" rid="hanspub.43469-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.43469-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.43469-ref17">17</xref>]。癌细胞的迁移和侵袭是异质性和适应性的过程，包括细胞形态的改变、细胞极性的丧失和最终导致易位的细胞运动性的增加。癌症侵袭也是导致癌症患者死亡的主要原因转移的原因 [<xref ref-type="bibr" rid="hanspub.43469-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.43469-ref19">19</xref>]。原发部位的肿瘤细胞可以发生EMT来获得运动能力和侵袭能力，EMT是肿瘤细胞转移的一个关键步骤。EMT已被证实参与多种生物过程，如伤口愈合、胚胎发育和癌症进展。已有研究发现，EMT参与了甲状腺癌的发展和甲状腺癌的局部侵袭转移 [<xref ref-type="bibr" rid="hanspub.43469-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.43469-ref21">21</xref>]。既往研究表明lncRNA PCAT14在前列腺癌中发挥重要作用，证明了其可作为前列腺癌的诊断标志物，且lncRNA PCAT14在前列腺癌中表达量明显高于癌旁正常组织 [<xref ref-type="bibr" rid="hanspub.43469-ref22">22</xref>]。本研究通过TCGA数据库分析发现，lncRNA PCAT14在甲状腺癌组织中低表达，通过转染上调TPC-1细胞中lncRNA PCAT14的表达，TPC-1细胞的增殖及侵袭能力均受到显著抑制，lncRNA PCAT14表达的上调抑制了EMT相关蛋白的表达，表明甲状腺癌中lncRNA PCAT14的异常低表达与甲状腺肿瘤的发生发展密切相关。RNA-蛋白互作预测分析发现lncRNA PCAT14可能与DBX2结合发挥生物学功能。同时，TCGA数据库显示在Ⅲ期和Ⅳ期甲状腺癌患者肿瘤组织内lncRNA PCAT14相对表达量更低，进一步表明lncRNA PCAT14与肿瘤进展相关，lncRNA PCAT14可能成为甲状腺癌治疗靶点和预后标志物。</p></sec><sec id="s8"><title>4. 结论</title><p>综上所述，lncRNA PCAT14在甲状腺癌和癌旁组织中有显著差异性表达且在癌组织中低表达，lncRNA PCAT14的相对低表达与甲状腺癌患者临床分期具有相关性。上调甲状腺癌细胞中lncRNA PCAT14的表达显著抑制肿瘤细胞的侵袭转移能力，其分子机制可能是lncRNA PCAT14通过与DBX2结合发挥生物学功能。</p></sec><sec id="s9"><title>文章引用</title><p>宋烨梅,华 慧,李晓琴. lncRNA PCAT14对甲状腺癌细胞侵袭转移的影响Effects of lncRNA PCAT14 on Invasion and Metastasis of Thyroid Cancer Cells[J]. 临床医学进展, 2021, 11(06): 2857-2865. https://doi.org/10.12677/ACM.2021.116415</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43469-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Parkin, D.M., Bray, F., Ferlay, J. and Pisani, P. (2005) Global Cancer Statistics, 2002. CA: A Cancer Journal for Clinicians, 55, 74-108. &lt;br&gt;https://doi.org/10.3322/canjclin.55.2.74</mixed-citation></ref><ref id="hanspub.43469-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Gharib, H., Papini, E., Paschke, R., Duick, D.S., Valcavi, R., Hegedus, L., et al. (2010) American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules. Journal of Endocrinological Investigation, 33, 287-291. &lt;br&gt;https://doi.org/10.1007/BF03346587</mixed-citation></ref><ref id="hanspub.43469-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Akkas, B.E., Demirel, B.B. and Vural, G.U. (2014) Prognostic Factors Affecting Disease-Specific Survival in Patients with Recurrent and/or Metastatic Differentiated Thyroid Carcinoma Detected by Positron Emission Tomography/Computed Tomography. Thyroid, 24, 287-295. &lt;br&gt;https://doi.org/10.1089/thy.2013.0195</mixed-citation></ref><ref id="hanspub.43469-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Kitahara, C.M. and Sosa, J.A. (2016) The Changing Incidence of Thyroid Cancer. Nature Reviews Endocrinology, 12, 646-653. &lt;br&gt;https://doi.org/10.1038/nrendo.2016.110</mixed-citation></ref><ref id="hanspub.43469-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Cabanillas, M.E., McFadden, D.G. and Durante, C. (2016) Thyroid Cancer. Lancet, 388, 2783-2795.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(16)30172-6</mixed-citation></ref><ref id="hanspub.43469-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Fagin, J.A. and Wells Jr., S.A. (2016) Biologic and Clinical Perspectives on Thyroid Cancer. The New England Journal of Medicine, 375, 1054-1067. &lt;br&gt;https://doi.org/10.1056/NEJMra1501993</mixed-citation></ref><ref id="hanspub.43469-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Regalbuto, C., Frasca, F., Pellegriti, G., Malandrino, P., Marturano, I., Di Carlo, I., et al. (2012) Update on Thyroid Cancer Treatment. Future Oncology, 8, 1331-1348. &lt;br&gt;https://doi.org/10.2217/fon.12.123</mixed-citation></ref><ref id="hanspub.43469-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Blomberg, M., Feldt-Rasmussen, U., Andersen, K.K. and Kjaer, S.K. (2012) Thyroid Cancer in Denmark 1943-2008, before and after Iodine Supplementation. International Journal of Cancer, 131, 2360-2366.  
&lt;br&gt;https://doi.org/10.1002/ijc.27497</mixed-citation></ref><ref id="hanspub.43469-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Guttman, M., Amit, I., Garber, M., French, C., Lin, M.F., Feldser, D., et al. (2009) Chromatin Signature Reveals over a Thousand Highly Conserved Large Non-Coding RNAs in Mammals. Nature, 458, 223-227.  
&lt;br&gt;https://doi.org/10.1038/nature07672</mixed-citation></ref><ref id="hanspub.43469-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Gong, J., Li, Y., Liu, C.J., Xiang, Y., Li, C., Ye, Y., et al. (2017) A Pan-Cancer Analysis of the Expression and Clinical Relevance of Small Nucleolar RNAs in Human Cancer. Cell Reports, 21, 1968-1981.  
&lt;br&gt;https://doi.org/10.1016/j.celrep.2017.10.070</mixed-citation></ref><ref id="hanspub.43469-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Rupaimoole, R., Calin, G.A., Lopez-Berestein, G. and Sood, A.K. (2016) miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discovery, 6, 235-246. &lt;br&gt;https://doi.org/10.1158/2159-8290.CD-15-0893</mixed-citation></ref><ref id="hanspub.43469-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Esteller, M. (2011) Non-Coding RNAs in Human Disease. Nature Reviews Genetics, 12, 861-874.  
&lt;br&gt;https://doi.org/10.1038/nrg3074</mixed-citation></ref><ref id="hanspub.43469-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">White, N.M., Zhao, S.G., Zhang, J., Rozycki, E.B., Dang, H.X., McFadden, S.D., et al. (2017) Multi-Institutional Analysis Shows That Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer. European Urology, 71, 257-266. &lt;br&gt;https://doi.org/10.1016/j.eururo.2016.07.012</mixed-citation></ref><ref id="hanspub.43469-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y., Hu, Y., Wu, G., Yang, Y., Tang, Y., Zhang, W., et al. (2017) Long Noncoding RNA PCAT-14 Induces Proliferation and Invasion by Hepatocellular Carcinoma Cells by Inducing Methylation of miR-372. Oncotarget, 8, 34429-34441. &lt;br&gt;https://doi.org/10.18632/oncotarget.16260</mixed-citation></ref><ref id="hanspub.43469-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Song, E., Jeon, M.J., Oh, H.S., Han, M., Lee, Y.M., Kim, T.Y., et al. (2018) Do Aggressive Variants of Papillary Thyroid Carcinoma Have Worse Clinical Outcome than Classic Papillary Thyroid Carcinoma? European Journal of Endocrinology, 179, 135-142. &lt;br&gt;https://doi.org/10.1530/EJE-17-0991</mixed-citation></ref><ref id="hanspub.43469-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, C., Cheng, T., Zheng, X., Hong, S., Liu, S., Liu, J., et al. (2018) Clinical Behaviors of Rare Variants of Papillary Thyroid Carcinoma Are Associated with Survival: A Population-Level Analysis. Cancer Management and Research, 10, 465-472. &lt;br&gt;https://doi.org/10.2147/CMAR.S157823</mixed-citation></ref><ref id="hanspub.43469-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Vuong, H.G., Long, N.P., Anh, N.H., Nghi, T.D., Hieu, M.V., Hung, L.P., et al. (2018) Papillary Thyroid Carcinoma with Tall Cell Features Is as Aggressive as Tall Cell Variant: A Meta-Analysis. Endocrine Connections, 7, R286-R293. 
&lt;br&gt;https://doi.org/10.1530/EC-18-0333</mixed-citation></ref><ref id="hanspub.43469-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Nixon, I.J., Simo, R., Newbold, K., Rinaldo, A., Suarez, C., Kowalski, L.P., et al. (2016) Management of Invasive Differentiated Thyroid Cancer. Thyroid, 26, 1156-1166. &lt;br&gt;https://doi.org/10.1089/thy.2016.0064</mixed-citation></ref><ref id="hanspub.43469-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Stuelten, C.H., Parent, C.A. and Montell, D.J. (2018) Cell Motility in Cancer Invasion and Metastasis: Insights from Simple Model Organisms. Nature Reviews Cancer, 18, 296-312. &lt;br&gt;https://doi.org/10.1038/nrc.2018.15</mixed-citation></ref><ref id="hanspub.43469-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Richards, E.J., Zhang, G., Li, Z.P., Permuth-Wey, J., Challa, S., Li, Y., et al. (2015) Long non-coding RNAs (LncRNA) Regulated by Transforming Growth Factor (TGF) β: LncRNA-Hit-Mediated TGFβ-Induced Epithelial to Mesenchymal Transition in Mammary Epithelia. The Journal of Biological Chemistry, 290, 6857-6867.  
&lt;br&gt;https://doi.org/10.1074/jbc.M114.610915</mixed-citation></ref><ref id="hanspub.43469-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Braun, J., Hoang-Vu, C., Dralle, H. and Huttelmaier, S. (2010) Down-Regulation of MicroRNAs Directs the EMT and Invasive Potential of Anaplastic Thyroid Carcinomas. Oncogene, 29, 4237-4244. &lt;br&gt;https://doi.org/10.1038/onc.2010.169</mixed-citation></ref><ref id="hanspub.43469-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Shukla, S., Zhang, X., Niknafs, Y.S., Xiao, L., Mehra, R., Cieslik, M., et al. (2016) Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. Neoplasia, 18, 489-499.  
&lt;br&gt;https://doi.org/10.1016/j.neo.2016.07.001</mixed-citation></ref></ref-list></back></article>